Pulmonary Arterial Hypertension

The AJMC® Pulmonary Arterial Hypertension compendium is a comprehensive resource for clinical news and expert insights for the progressive disorder, which is characterized by high blood pressure in the arteries that go from the heart to the lungs.

Latest News

Tricuspid Regurgitation | Image Credit: © Richelle-stock.adobe.com
Tricuspid Regurgitation Reliable Prognostic Indicator of PAH Severity

August 13th 2025

Despite knowledge of the benefits of right heart hemodynamic measures for evaluating patient prognosis in the setting of pulmonary arterial hypertension (PAH), gaps remain in a defined role for tricuspid regurgitation as it relates to echocardiographic phenotype.

Lungsandheart | Image Credit: Kiattisak-stock.adobe.com
Genetic Study Finds Hypothyroidism May Increase PAH Risk

July 25th 2025

Lung transplant | Image Credit: Pixel-Shot-stock.adobe.com
Lung Transplant Referrals Lag for High-Risk Patients With PAH

July 18th 2025

PAH | Image Credit: Maggie-sora.chatgpt.com
FDA Reviewing Sotatercept-csrk Label Expansion for PAH

July 14th 2025

PAH image | Image Credit: Kiattisak-stock.adobe.com
Global Study Warns of Rising PAH Burden

July 9th 2025

Transforming PAH Management Through Innovation and Strategic Care

Learn how novel therapies, early diagnosis, and personalized treatment approaches are advancing PAH care while addressing clinical needs, patient preferences, and economic impact.

AJMC Stakeholder Summit logo displayed on a light blue and white scientific background with hexagonal molecular graphics and connecting lines.

More News

Man with hand on head
July 28th 2022

How Much Do Physicians Know About SDOH in Their Patients With PAH?

Alisha Lekh
Clinicians interviewed in a recent study reported various social determinants of health (SDOH) affecting health outcomes for patients with pulmonary arterial hypertension (PAH), indicating the need to address SDOH in PAH care.
Neon-enhanced heart image
July 19th 2022

HFpEF-PH Improves Following Treatment With Sacubitril/Valsartan

Maggie L. Shaw
Several measures of hemodynamic capacity were improved in this study that evaluated sacubitril/valsartan use for heart failure with preserved ejection fraction and pulmonary hypertension (HFpEF-PH).
Image of a person deciding on which path to take
July 12th 2022

Functional Capacity Dropped Among Patients With PAH Following COVID-19 Lockdown

Maggie L. Shaw
A Belgian study compared exercise performance before and after COVID-19 lockdown measures were swiftly implemented in the country among patients with preexisting pulmonary arterial hypertension (PAH).
Image of heart and lungs
July 8th 2022

New Findings May Have Implications for PH Classification

Jaime Rosenberg
Researchers have found that patients who have idiopathic pulmonary arterial hypertension (IPAH) with a phenotype characterized by a smoking history and low diffusion capacity for carbon monoxide had little in common with patients with classical IPAH.
white pills lined up
June 29th 2022

Monotherapy May Be Preferred Over Combination Therapy for Specific Patients With PAH

Lindsey Mulrooney
Despite current guidelines recommending combination therapy, there are certain patients with pulmonary arterial hypertension (PAH) who remain on monotherapy for specific reasons.
Image of blood in test tubes
June 23rd 2022

Study Highlights Need for Validated Blood Biomarkers in PAH

Jaime Rosenberg
Collecting more than 3 decades’ worth of data, researchers determined that none of the identified blood biomarkers are accurate enough to take the place of current diagnostic approaches, either due to lack of data or lack of specificity.
Gary Owens, MD
June 5th 2022

Dr Gary Owens Discusses Patient-Centered Care in PAH

Gianna Melillo
Gary Owens, MD, president of Gary Owens Associates, explains the importance of shared decision making and patient-centered care in pulmonary arterial hypertension (PAH).
Intestinal Microbiota May Potentially Serve as Therapeutic Target in PAH
June 4th 2022

Intestinal Microbiota May Potentially Serve as Therapeutic Target in PAH

Jaime Rosenberg
Gary Owens, MD
May 25th 2022

Dr Gary Owens Describes Treatments in the Pipeline for PAH

Gianna Melillo
Gary Owens, MD, president of Gary Owens Associates, describes mechanisms, trials of treatments in the works for pulmonary arterial hypertension (PAH).
Site Logo
May 16th 2022

Researchers Highlight Risks of RHC in Pediatric Patients With PAH

Jaime Rosenberg
Based on their findings, the researchers of the retrospective study are calling for close evaluation, careful monitoring, and appropriate treatment to mitigate complications and mortality.
graphic of lungs
May 8th 2022

Novel Therapies Targeting Vasoconstriction and Vascular Remodeling May Improve Outcomes in PAH

Rose McNulty
Drugs currently marketed for pulmonary arterial hypertension have been able to extend the lives of patients but have shown limitations in their ability to prevent or reverse the disease. A novel combination approach may hold promise in future treatments.
Gary Owens, MD
May 2nd 2022

Dr Gary Owens on the Future of PAH Research

Gianna Melillo
Gary Owens, MD, president of Gary Owens Associates, discusses current treatments available for pulmonary arterial hypertension (PAH) and where future directions in research may lead.
Image of lungs
April 28th 2022

Review: Investigational Therapies Could Transform PAH Treatment

Jared Kaltwasser
A new commentary suggests new pathways might lead to a major shift in the treatment of pulmonary arterial hypertension (PAH).
Gary Owens, MD
April 25th 2022

Dr Gary Owens Explains Opportunities to More Efficiently Identify, Diagnose PAH

Gianna Melillo
Gary Owens, MD, president of Gary Owens Associates, outlines the current epidemiological knowledge of pulmonary arterial hypertension (PAH).
Image of lungs and stethoscope
April 21st 2022

Review Says Therapies Are Boosting Survival From PAH

Jared Kaltwasser
A new review article shows positive trends in survival, as scientists better understand the different types and symptoms of pulmonary arterial hypertension (PAH).
Dapagliflozin Combo Is Not More Effective in Reducing PAH in Preclinical Study
April 16th 2022

Dapagliflozin Combo Is Not More Effective in Reducing PAH in Preclinical Study

Mary Caffrey
The study used rats with monocrotaline (MCT)-induced PAH to examine whether adding dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, would offer any add-on benefit when used with sildenafil.
Image of a doctor and patient talking
April 5th 2022

Mental Disorders Common in Patients With CTEPH

Jared Kaltwasser
Panic disorders and specific phobias were the mental disorders most often seen among individuals who have chronic thromboembolic pulmonary hypertension (CTEPH), according to new research.
Image of patient monitoring
March 31st 2022

Enhancing Hemodynamic Parameters in Acute Decompensated Right Heart Failure in Patients With CTD-PAH

Jared Kaltwasser
Levosimendan appeared to increase in-hospital survival rates, although no long-term survival benefit was reported, among patients with comorbid heart failure and connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH).
Graphic of how people are interconnected
March 25th 2022

Age, Gender Impact Survival With IPAH, Finds South Korean Study

Jaime Rosenberg
Drawing on over a decade’s worth of data, new research shows that the 10-year survival of over 9000 patients with idiopathic pulmonary arterial hypertension (IPAH) was 57%.
Pants with measuring tape
March 18th 2022

Mystery Remains Around Obesity’s Association With Better PAH Outcomes

Jaime Rosenberg
Based on their findings, the investigators argue a need for more inclusive representation of patients with pulmonary arterial hypertension (PAH) across the weight spectrum.
heart graphic
March 12th 2022

Elevated Repolarization Dispersion Linked With LV Diastolic Discoordination in Pediatric PAH

Rose McNulty
Repolarization dispersion has been linked to echocardiographic measures of diastolic dysfunction in past research, and a recent study found it potentially indicative of pulmonary arterial hypertension severity.
workers in lab
March 11th 2022

Hematological Markers Hold Promise as Prognostic Tools in PAH Associated With Congenital Heart Disease

Rose McNulty
A recent study found that a selection of non-invasive markers could help identify high-risk children with pulmonary arterial hypertension associated with congenital heart disease.
lung graphic
March 4th 2022

Increased Rates of Depression, Anxiety Seen in Patients With PAH

Rose McNulty
A small study in northwestern China suggests earlier detection of depression and anxiety in patients with pulmonary arterial hypertension may improve patient quality of life.
Image of an Asian Couple
February 25th 2022

Review Finds Sildenafil Safe, Effective for PAH Treatment in Asian Adults

Rose McNulty
Studies focused on Asian populations with pulmonary arterial hypertension (PAH) treated with sildenafil are rare, and a new meta-analysis has found the phosphodiesterase-5 inhibitor effective in this understudied subgroup.
Image of doctor and pediatric patient
February 23rd 2022

Analysis Points to Potential Biomarker for Pediatric PAH

Jared Kaltwasser
The circulating RNA hsa_circ_0003416 appears to be downregulated in patients with pulmonary arterial hypertension (PAH), according to new research.
Image of lungs
February 18th 2022

Metabolic Differences Between Endothelial Cells in PH Phenotypes Explained

Rose McNulty
This new study aimed to identify metabolic differences in endothelial cells in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (PH) to aid in the development of novel therapeutic approaches.
Image of study evidence
February 15th 2022

Cytokine Profiles May Signal High Risk of PAH in Patients With Systemic Sclerosis

Jared Kaltwasser
High-risk patients and patients with a history of pulmonary arterial hypertension (PAH) had significantly different cytokine profiles compared with patients with a low risk of the condition.
child and adult hand
February 10th 2022

Early Intervention, Combination Therapy Improve Outcomes in Pediatric PAH

Jared Kaltwasser
A new report outlines helpful strategies for pediatric patients with pulmonary arterial hypertension, although experts say more research is needed to catch up with advances in the field.
Routine Lung CT Reports Have Diagnostic and Prognostic Utility in Pulmonary Hypertension Subtypes
February 5th 2022

Routine Lung CT Reports Have Diagnostic and Prognostic Utility in Pulmonary Hypertension Subtypes

Rose McNulty
Idiopathic pulmonary arterial hypertension and pulmonary hypertension due to chronic lung disease can be difficult to differentiate, but new research suggests descriptions of lung parenchyma in routine CT scans may prove useful.
lung graphic
January 31st 2022

Biomarkers Emerging to Track Pulmonary Hypertension, But Picture Remains Complex

Jared Kaltwasser
Although a number of biomarkers can be used to track features of pulmonary hypertension, no single biomarker is sufficient, according to a new review.
<123456789>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo